- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Inclusion of Generic Drugs in Pathways
Peter Salgo, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; and Bryan Loy, MD, discuss the factors influencing the inclusion of brand name and generic agents in medical oncology pathways.
Dr Kolodziej explains that the results of randomized clinical trials have shown the equivalence of certain generic treatment regimens to regimens that incorporate branded drugs. However, despite these results, not all pathways incorporate the use of generics.
Providers consider many factors when selecting a branded oncology drug over a generic, comment Drs Kolodziej and Klein. The first consideration is minimizing toxicity, followed by safety; last comes economics, according to Klein. Patient-specific factors also play a role, adds Kolodziej. For example, trastuzumab is always included in pathways for patients with HER-2-positive breast cancer.
Dr Salgo notes that when making treatment decisions, providers often feel pressured to adhere to a pathway to ensure that treatment is covered by insurance. However, Drs Klein, Loy, and Fox explain that programs have been established to ensure that providers can still treat their patients outside of a pathway.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
